Table 1 Baseline characteristics
Variable | All patients (n=63) | Diabetic (n=28) | Non-diabetic (n=35) | p-value |
|---|---|---|---|---|
Age (yrs) | 70 Ā±11 | 70Ā±10 | 72Ā±10 | 0.04 |
Male (%) | 37 (59) | 18 (64) | 19 (54) | 0.42 |
BMI (kg/m2) | 26.3 Ā± 3.9 | 28.1Ā±4.0 | 24.8Ā±3.2 | 0.001 |
SBP (mmHg) | 137 Ā± 21 | 135Ā±16 | 138Ā±24 | 0.55 |
DBP (mmHg) | 76Ā±11 | 75Ā±12 | 77Ā±11 | 0.64 |
HR (beats/min) | 70 Ā± 14 | 69Ā±12 | 71Ā±16 | 0.59 |
Dyspnea status (%) | Ā | Ā | Ā | Ā |
āāNYHA I | 12 (19) | 7 (25) | 5 (14) | 0.83 |
āāNYHA II | 39 (62) | 16 (57) | 23 (66) | 0.65 |
āāNYHA III | 12 (19) | 5 (18) | 7 (20) | 0.72 |
Coronary risk factors (%) | Ā | Ā | Ā | Ā |
āāHypertension | 45 (71) | 19 (48) | 26 (71) | 0.58 |
āāCurrent smoking | 27 (43) | 12 (43) | 15 (43) | 0.99 |
āāHypercholesterolemia | 32 (51) | 14 (50) | 18 (51) | 0.91 |
āāFamily history of cardiovascular | 4 (6) | 2 (7) | 2 (5) | 0.82 |
āādisease | Ā | Ā | Ā | Ā |
Previous coronary artery disease (%) | 26 (41) | 11 (39) | 15 (43) | 0.78 |
Medications (%) | Ā | Ā | Ā | Ā |
āāACE inhibitors/ARB | 38 (62) | 16 (57) | 22 (63) | 0.44 |
āāBeta-blockers | 30 (48) | 12 (43) | 18 (51) | 0.50 |
āāCalcium antagonists | 25 (40) | 10 (36) | 15 (43) | 0.56 |
Diabetic characteristics | Ā | Ā | Ā | Ā |
Duration of diabetes (yrs) | - | 12.0Ā±8.8 | - | - |
HbA1c (%) | - | 7.0Ā±2.4 | - | - |
Insulin therapy (%) | - | 20 (71) | - | - |
Oral therapy (%) | Ā | 12 (43) | Ā | Ā |
āāMetformin therapy (%) | - | 8 (29) | - | - |
Retinopathy (%) | - | 11 (39) | - | - |
Peripheral arterial disease (%) | - | 15 (54) | - | - |
āāSupra aortic | - | 6 (21) | - | - |
āāLower limb | - | 11 (39) | - | - |